Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
28 February 2019 | Story Lacea Loader
A group of outsourced workers and some students blocked entrances to gates of the University of the Free State (UFS) Bloemfontein Campus this morning. This follows the unprotected strike action by outsourced workers yesterday to demonstrate their demand for immediate insourcing of all jobs at the university.

The protest is ongoing, and the executive management is continuing engagement with the WSF today regarding their proposed demand for insourcing.

All academic and administrative services and activities are continuing as normal today, after some classes were disrupted yesterday and spaces on campus vandalised. The situation on campus is being monitored closely by our Protection Services and members of the university management.

The executive management remains committed to ensuring stability on campus and to the uninterrupted continuation of all academic and administrative services and activities; the executive management is furthermore committed to engage continuously with all its constituencies, including the WSF, in an open, transparent, and honest manner.

All students and staff are encouraged to constantly check the official communication platforms for updated information.

Emergency numbers for the Bloemfontein Campus:
+27 51 401 2911/2634 (24 hours on duty)

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393


28 February 2019: Outsourced workers at the UFS embark on unprotected strike action
Outsourced workers at the University of the Free State (UFS) withdrew their labour today to demonstrate their demand for immediate insourcing of all jobs at the university. Some students and student organisations exercised their solidarity with this intended action and participated in an unprotected strike on the Bloemfontein Campus.

The unprotected strike action follows the handing over of a memorandum by a group consisting of students and outsourced workers from the Workers & Students Forum (WSF) to the university’s executive management during the Shimla Park Commemoration Prayer Service, which took place on the Bloemfontein Campus on Friday 22 February 2019.

In response to the memorandum demanding insourcing, the executive management indicated the university management’s commitment to engaging with the WSF for the betterment of outsourced workers at the UFS and its community. The response furthermore indicated a request to initiate a formal process of engagement and consultation on the proposed outsourcing. The WSF did not accede to this request and decided to embark on today’s unprotected strike action.

Although academic and administrative services and activities continued as normal today, disruption of some classes occurred on the Bloemfontein Campus. The university’s executive management, together with its Protection Services, is monitoring the situation closely. Students participating in the unprotected strike action have been requested to uphold the right to education of their fellow students and not to participate in the disruption of classes.

Discussions regarding possible insourcing at the UFS commenced in 2016, and in 2017 an agreement was reached on a decent or living wage at the UFS. As a result, the total remuneration package of employees of service providers was increased to R7 000 as from 1 July 2017. It was furthermore agreed that the contracts with the current service providers will be rolled over until 2020. A team representing the UFS Council, the Mutual Forum (comprising NEHAWU and UVPERSU), and the Workers Forum (comprising representatives of employees of service providers at the UFS), participated in the discussions.

Additional to the agreement on a decent living wage at the UFS reached in 2017, the university management also established a service provider and contractor forum and subsequently appointed a compliance officer, who meets on a quarterly basis with representatives of the service providers and contractors to resolve issues on a real-time basis and to ensure that they are dealt with in a fair and amicable way, thus ensuring that our outsourced workers are treated in a manner which is aligned to the values of the UFS.

The executive management remains committed to engage continuously with all its constituencies, including the WSF, in an open, transparent, and honest manner.

Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept